From: Factors influencing global antiretroviral procurement prices
Antiretroviral drugs+ | ABC 300 mg | ddI 100 mg | ddI 400 mg | LPV/r 133/33 mg | RTV 100 mg | TDV 300 mg |
---|---|---|---|---|---|---|
HIV Prevalence 2-5% | -0.060 (-0.181, 0.061) | -0.109 (-0.298, 0.080) | -0.509** (-0.663, -0.354) | -0.405* (-0.785, -0.024) | -0.107 (-0.453, -0.239) | -0.126* (-0.222, -0.031) |
HIV Prevalence >5% | -0.092 (-0.247, 0.063) | -0.167 (-0.335, -0.002) | -0.343** (-0.417, -0.269) | -0.629* (-1.015, -0.244) | -0.382 (-1.041, 0.277) | -0.137* (-0.265, 0.010) |
Lower-middle-income | -0.018 (-0.155, 0.118) | 0.227 (-0.417, 0.871) | 0.573 (0.199, 0.948) | 0.657 (0.033, 1.282)* | -0.050 (-0.328, 0.428) | 0.165 (-0.006, 0.337) |
Upper-middle-income | -0.040 (-0.278, 0.198) | 0.407 (0.129, 0.684)* | 0.369 (0.063, 0.676)* | 0.284 (-0.373, 0.942) | -0.049 (-0.313, 0.410) | 0.272* (0.076, 0.467) |
Volume 2nd tercile | -0.006 (-0.123, 0.111) | 0.010 (-0.165, 0.185) | 0.146 (-0.096, 0.388) | -0.039 (-0.336, 0.257) | 0.017 (0.536, 0.501) | -0.117 (-0.256, 0.022) |
Volume 3th tercile | -0.003 (-0.109, 0.103) | 0.023 (-0.190, 0.235) | 0.118 (-0.273, 0.509) | -0.410* (-0.637, -0.182) | -0.405* (-0.785, -0.025) | -0.158 (-0.329, 0.012) |
API*** | -0.004 (-0.007, 0.002) | 0.008 (-0.011, 0.026) | -0.012 (-0.027, -0.004) | -0.006 (-0.018, 0.006) | 0.007 (-0.013, 0.027) | 0.001 (0.002, 0.004) |
Innovator | 0.662** (0.451, 0.873) | 0.571** (0.411, 0.730) | 0.148* (0.051, 0.245) | -0.714** (-0.989, -0.438) | -0.793 (-1.789, 0.204) | 0.274** (-0.138, 0.410) |
CHAI++ | -0.143* (-0.274, -0.012) | -0.499 (-1.099, 0.102) | -0.550* (-0.982, -0.117) | -0.279* (-0.499, 0.060) | -0.666** (-1.098, -0.235) | -0.193 (-0.582, 0.197) |
PEPFAR+++ | 0.054 (-0.049, 0.157) | 0.046 (-0.265, 0.358) | 0.347 (0.092, 0.785) | 0.486* (0.091, 0.880) | -0.118* (-0.233, 0.002) | 0.084 (-0.040, 0.209) |
R-square | 0.578 | 0.455 | 0.481 | 0.269 | 0.221 | 0.408 |
Observations | 793 | 492 | 397 | 484 | 309 | 489 |